Evidence map›Paper›PMID 10623373›Full record

ReviewPharmacoEconomics1999

Influenza. The role of burden-of-illness research.

T D Szucs

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in PharmacoEconomics, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. The impact of influenza-like illness in young children on their parents: a quality of life survey.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Vacunas · 2005
    Article
  13. Virological surveillance of influenza-like illness in the community using PCR and serology.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2004
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

T D SzucsDepartment of Medical Economics, University Hospital, Zürich, Switzerland.
University Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza is associated with a significant economic burden on both society and the individual, resulting in considerable healthcare costs and loss of productivity, as well as intangible costs such as suffering, grief and social disruption. The incidence and severity of influenza infection depend, at least in part, on the age and health status of the population. For example, the incidence of influenza is relatively high among children and young adults, but serious complications are much more likely to occur among the very young (< 1 year of age) and the elderly (> 65 years of age). School absenteeism tends to peak in the first half of a typical 6- to 8-week influenza epidemic, followed by workplace absenteeism in the latter half as school-aged children pass the infection to family members. Cost-of-illness studies are used by policy-makers to justify budgets and set priorities for prevention programmes, research and other expenditures. On the basis of German Sickness Fund data, recent estimates indicate that the cost of an influenza epidemic in that country is approximately 2 billion Deutschmarks (approximately $US1.4 billion). The bulk of these costs reflects indirect costs associated with lost productivity, a finding also noted in an earlier French cost-of-illness study of influenza. Thus, the main economic burden of influenza falls on infected individuals, their employers and their relatives. Methodology used in cost-of-illness studies can be quite variable. For example, two main approaches are used in measuring indirect costs (human capital and willingness to pay), although there is controversy as to which is the preferred method. Thus, investigators involved in cost-of-illness studies must be explicit regarding study methodology in order to allow for appropriate interpretation of study results by interested parties.

Indexed as

Cost of IllnessFranceHealth Care CostsHumansInfluenza, HumanResearchSeverity of Illness Index

Identifiers

PMID10623373
OpenAlexW2028350992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.